Daily Stock Analysis, CHMA, Chiasma Inc, priceseries

Chiasma Inc. Daily Stock Analysis
Stock Information
Open
1.55
Close
1.60
High
1.60
Low
1.50
Previous Close
1.55
Daily Price Gain
0.05
YTD High
1.80
YTD High Date
Jan 30, 2018
YTD Low
1.40
YTD Low Date
Feb 9, 2018
YTD Price Change
-0.10
YTD Gain
-5.88%
52 Week High
2.95
52 Week High Date
Oct 10, 2017
52 Week Low
1.25
52 Week Low Date
Aug 3, 2017
52 Week Price Change
0.00
52 Week Gain
0.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 23. 2017
1.90
Sep 7. 2017
2.12
10 Trading Days
11.62%
Link
LONG
Sep 11. 2017
2.15
Sep 26. 2017
2.37
11 Trading Days
10.25%
Link
LONG
Sep 27. 2017
2.45
Oct 11. 2017
2.68
10 Trading Days
9.29%
Link
Company Information
Stock Symbol
CHMA
Exchange
NasdaqGS
Company URL
http://www.chiasmapharma.com
Company Phone
617-928-5300
CEO
Mark J. Fitzpatrick
Headquarters
Massachusetts
Business Address
275 WYMAN STREET, SUITE 250, WALTHAM, MA 02451
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001339469
About

Chiasma, Inc. operates as a pharmaceutical company, which engages in developing and commercializing oral forms of therapies that are available by injection. Its products include octreotide capsules and clinical trials. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin on April 12, 2001 and is headquartered in Waltham, MA.

Description

Chiasma, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases. Its product candidate is octreotide capsules or MYCAPSSA, which has completed Phase III clinical trial for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massachusetts.